Haemorrhagic fever with renal syndrome bivalent vaccine (Gerbil Kidney Cell, Zhejiang Tianyuan Bio-Pharmaceutical)

双价肾综合征出血热灭活疫苗（浙江天元生物）

Report date: 2022/01/14 13:23:58

Base Information

Drug NameHaemorrhagic fever with renal syndrome bivalent vaccine (Gerbil Kidney Cell, Zhejiang Tianyuan Bio-Pharmaceutical)
Drug Alias Name佑尔健
ClassificationVaccines > Vaccine type > Multivalent vaccineVaccines > National Immunization Program > Non-immunization program vaccine(Class II)Vaccines > Application > Prophylactic vaccine
Mechanisms of ActionImmunostimulants
TargetsNot applicable
Therapy Area/IndicationsHemorrhagic Fevers, Viral
Global Approved IndicationsHemorrhagic Fevers, Viral
Approved Indications in ChinaHemorrhagic Fevers, Viral
Original Approved Country/TerritoryMainland China
Original Approved Date1999/01/01
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesZhejiang Tianyuan Bio-Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesN/A
Active IndicationsHemorrhagic Fevers, Viral
Inactive IndicationsN/A

Other Information

ATC CodeJ07BX
Related LinksWikipedia